According to Natco Pharma 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 16.1584. At the end of 2022 the company had a P/E ratio of 26.4.
Year | P/E ratio | Change |
---|---|---|
2022 | 26.4 | -56.31% |
2021 | 60.4 | 66.07% |
2020 | 36.3 | 63.99% |
2019 | 22.2 | 45.46% |
2018 | 15.2 | -49.34% |
2017 | 30.1 | 11.9% |
2016 | 26.9 | -58.62% |
2015 | 64.9 | 33.6% |
2014 | 48.6 | 71.75% |
2013 | 28.3 | 44.05% |
2012 | 19.6 |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.